Traws Pharma, Inc.
Traws Pharma is a clinical stage biopharmaceutical company dedicated to developing novel therapies for respiratory viral diseases and cancer. The company focuses on advancing investigational antiviral agents targeting viruses such as influenza, COVID-19, and bird flu, as well as developing proprietary cancer treatments. With a commitment to patient safety and accelerated clinical strategies, Traws aims to address unmet medical needs and medical challenges related to viral infections and cancer.
Industries
Nr. of Employees
small (1-50)
Traws Pharma, Inc.
Patents
Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US-12156856-B2
View DetailsFormulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US-11382877-B2
View DetailsFormulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US-10098862-B1
View Details
Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US-12156856-B2
View DetailsFormulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability
US-11382877-B2
View DetailsFormulations with enhanced stability and bioavailability for administration of (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones
US-10098862-B1
View DetailsProducts
Oral Mpro (3CL protease) inhibitor — investigational COVID-19 therapy
Investigational oral small-molecule inhibitor of the SARS-CoV-2 main protease designed for monotherapy without a metabolic booster; completed Phase 1 safety and PK studies and planned Phase 2 evaluation.
Oral cap-dependent endonuclease inhibitor — investigational influenza therapy
Investigational oral small-molecule inhibitor of the influenza cap-dependent endonuclease intended for single-dose treatment or prophylaxis of seasonal and pandemic influenza, with demonstrated activity against drug-resistant and avian strains in preclinical studies and supportive Phase 1 PK/PD data.
Multi-kinase CDK4-plus inhibitor — investigational oncology therapy
Proprietary multi-kinase small-molecule inhibitor targeting CDK4-plus and other kinases, under dose-ranging Phase 1/2 evaluation for metastatic breast and endometrial cancers; preclinical data indicate activity in models resistant to existing CDK4/6 inhibitors and a potentially improved safety profile regarding marrow suppression.
Oral Mpro (3CL protease) inhibitor — investigational COVID-19 therapy
Investigational oral small-molecule inhibitor of the SARS-CoV-2 main protease designed for monotherapy without a metabolic booster; completed Phase 1 safety and PK studies and planned Phase 2 evaluation.
Oral cap-dependent endonuclease inhibitor — investigational influenza therapy
Investigational oral small-molecule inhibitor of the influenza cap-dependent endonuclease intended for single-dose treatment or prophylaxis of seasonal and pandemic influenza, with demonstrated activity against drug-resistant and avian strains in preclinical studies and supportive Phase 1 PK/PD data.
Multi-kinase CDK4-plus inhibitor — investigational oncology therapy
Proprietary multi-kinase small-molecule inhibitor targeting CDK4-plus and other kinases, under dose-ranging Phase 1/2 evaluation for metastatic breast and endometrial cancers; preclinical data indicate activity in models resistant to existing CDK4/6 inhibitors and a potentially improved safety profile regarding marrow suppression.
Services
Collaborative development and commercialization partnerships for investigational small-molecule therapeutics, including strategies for distribution and stockpiling.
Collaborative development and commercialization partnerships for investigational small-molecule therapeutics, including strategies for distribution and stockpiling.
Expertise Areas
- Clinical trial management
- Antiviral drug discovery and development
- Oncology small-molecule development
- Preclinical pharmacology and toxicology
Key Technologies
- AI/ML-guided medicinal chemistry
- In vitro antiviral susceptibility assays (EC50/EC90)
- Small-molecule protease inhibition (Mpro/3CL)
- Cap-dependent endonuclease inhibition
News & Updates
Traws Pharma received feedback from the FDA on development paths for tivoxavir marboxil for bird flu and seasonal flu, including on the use of the Animal Rule, to support accelerated development and potential approval.
The company reported financial results for Q1 2025 and provided updates on its investigational programs including tivoxavir marboxil for bird flu and seasonal flu, and ratutrelvir for COVID-19.
Financial results for 2024 and updates on the company's pipeline, including tivoxavir marboxil for bird flu and ratutrelvir for COVID-19.
Retirement of Werner Cautreels as CEO and appointment of Iain D. Dukes as Interim CEO.
An upcoming virtual investor event scheduled for March 31, 2025.
Positive data supporting ratutrelvir as a treatment for COVID-19 was presented at ICAR 2025.
Traws Pharma received feedback from the FDA on development paths for tivoxavir marboxil for bird flu and seasonal flu, including on the use of the Animal Rule, to support accelerated development and potential approval.
The company reported financial results for Q1 2025 and provided updates on its investigational programs including tivoxavir marboxil for bird flu and seasonal flu, and ratutrelvir for COVID-19.
Financial results for 2024 and updates on the company's pipeline, including tivoxavir marboxil for bird flu and ratutrelvir for COVID-19.
Retirement of Werner Cautreels as CEO and appointment of Iain D. Dukes as Interim CEO.
An upcoming virtual investor event scheduled for March 31, 2025.
Positive data supporting ratutrelvir as a treatment for COVID-19 was presented at ICAR 2025.